Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Neurocrine Biosciences (NASDAQ: NBIX) and has maintained a price target of $204 for the stock.